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Abstract
Importance
Epigenetic modifications of the genome, such as DNA methylation and histone modifica-
tions, have been reported to play a role in neurodegenerative diseases (ND) such as Alzhei-
mer’s disease (AD) and Parkinson’s disease (PD).
Objective
To systematically review studies investigating epigenetic marks in AD or PD.
Methods
Eleven bibliographic databases (Embase.com, Medline (Ovid), Web-of-Science, Scopus,
PubMed, Cinahl (EBSCOhost), Cochrane Central, ProQuest, Lilacs, Scielo and Google
Scholar) were searched until July 11th 2016 to identify relevant articles. We included all ran-
domized controlled trials, cohort, case-control and cross-sectional studies in humans that
examined associations between epigenetic marks and ND. Two independent reviewers,
with a third reviewer available for disagreements, performed the abstract and full text selec-
tion. Data was extracted using a pre-designed data collection form.
Results
Of 6,927 searched references, 73 unique case-control studies met our inclusion criteria.
Overall, 11,453 individuals were included in this systematic review (2,640 AD and 2,368 PD
outcomes). There was no consistent association between global DNA methylation pattern
and any ND. Studies reported epigenetic regulation of 31 genes (including cell communica-
tion, apoptosis, and neurogenesis genes in blood and brain tissue) in relation to AD and
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PD. Methylation at the BDNF, SORBS3 and APP genes in AD were the most consistently
reported associations. Methylation of α-synuclein gene (SNCA) was also found to be associ-
ated with PD. Seven studies reported histone protein alterations in AD and PD.
Conclusion
Many studies have investigated epigenetics and ND. Further research should include larger
cohort or longitudinal studies, in order to identify clinically significant epigenetic changes.
Identifying relevant epigenetic changes could lead to interventional strategies in ND.
Introduction
Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the most common neurodegenera-
tive disorders and are a major cause of disability and premature death among older people
worldwide [1–3]. Due to global population ageing, prevalence of AD and PD is expected to
increase, imposing a social and economic burden on society [4, 5]. The causes of most cases of
neurodegenerative diseases remain largely unknown. However, in the last decade great
advances have been made in our understanding of the pathogenetic mechanisms that lead to
AD and PD [6–8]. It has been accepted that there are several genetic causes that play a role in
the development of these disorders, including chromosome aberrations and gene mutations
[8, 9]. Additionally, environmental exposures have been suggested to play a crucial role in the
etiological process of neurodegenerative diseases. Both AD and PD are thought to be caused
by complicated interactions between genetic and environmental factors [10]. Despite improve-
ments in knowledge and understanding, there are currently no disease-modifying therapies
for these diseases. A large amount of the variance in the risk of developing neurodegenerative
diseases remains to be explained.
The epigenome is responsible for the molding and the three-dimensional structure of the
genomic material in the cell nucleus. It provides a bridge between genes and environment and
may help to improve our understanding on the etiology of complex diseases, AD, and PD [11].
Epigenetic mechanisms are known to alter gene expression or cellular phenotype in a heritable
manner [12]. DNA methylation and modifications of histone proteins are the most intensively
studied among the major epigenetic modifications. DNA methylation occurs when a methyl
group is added at a cytosine nucleotide that precede guanines (so-called CpG dinucleotides). It
further influences the function of DNA by activating or repressing the transcriptional activity
of a gene [12]. Posttranslational histone modifications, such as methylation and acetylation of
lysine residues on histone tails, are another type of epigenetic modification. Histone modifca-
tions affect gene expression mainly by altering chromatin structure [12, 13].
Clinical features of neurological disorders and results from epidemiological studies suggest
an epigenetic contribution to etiology of these diseases. Epigenetic modulation has been well
documented in brain development, plastic changes, and in brain diseases including AD and
PD. The most compelling evidence on the role of epigenetics on AD comes from the results of
treatment of AD patients with inhibitors of histone deacetylases (HDAC). HDAC is a key
enzyme involved in histone acetylation [14]. Also, in animal models of PD, HDAC inhibitor
inhibits α-synuclein toxicity in the dopamine neuron, a common neuropathological feature of
PD [15]. Dysregulation of DNA methylation in AD and PD patients is also well documented.
Recent evidence shows that AD patients have an elevated DNA methylation state of repetitive
elements [16]. Hypomethylation of the tumor necrosis factor (TNF) gene in cortex and higher
DNA Methylation and Neurodegenerative Diseases
PLOS ONE | DOI:10.1371/journal.pone.0167201 December 14, 2016 2 / 31
been financially supported by Erasmus Mundus
Western Balkans (ERAWEB), a project funded by
the European Commission. Additional support was
provided to AD from the Netherlands Organization
for Health Research (NWO) (ZonMW VENI
916.12.154) and the EUR Fellowship. BE and JT
worked as scientists at Metagenics Inc. OHF
reported receiving grants or research support from
Metagenics Inc. The funder provided research
support for KW, TM and OHF and support in the
form of salaries for JT, but did not have any
additional role in the study design, data collection
and analysis, decision to publish, or preparation of
the manuscript. The specific roles of these authors
are articulated in the "author contributions" section.
Competing Interests: KW and TM reported
receiving research support from Metagenics Inc.
JM, KD, JM, JN, BK and AZ have been financially
supported by Erasmus Mundus Western Balkans
(ERAWEB), a project funded by the European
Commission. Additional support was provided to
AD from the Netherlands Organization for Health
Research (NWO) (ZonMW VENI 916.12.154) and
the EUR Fellowship. BE and JT worked as
scientists at Metagenics Inc. OHF reported
receiving grants or research support from
Metagenics Inc. KW and TM reported receiving
research support from Metagenics Inc. JM, KD,
JM, JN, BK and AZ have been financially supported
by Erasmus Mundus Western Balkans (ERAWEB),
a project funded by the European Commission.
Additional support was provided to AD from the
Netherlands Organization for Health Research
(NWO) (ZonMW VENI 916.12.154) and the EUR
Fellowship. BE and JT worked as scientists at
Metagenics Inc. OHF reported receiving grants or
research support from Metagenics Inc. We confirm
that the funding currently declared in the
competing interest statement does not alter our
adherence to PLOS ONE policies on sharing data
and materials.
levels of TNF-α cytokine in the cerebrospinal fluid has been reported in patients with PD [17].
TNF-α is one of the main proinflammatory cytokines that play a central role in the inflamma-
tory response. TNF-α is also upregulated in AD patients and is involved in the pathogenesis of
AD [18]. In dopaminergic regions of post-mortem brains, decreased methylation of the α-
synuclein gene (SNCA) has been observed. The decreased methylation might be responsible
for the accumulation of the protein α-synuclein, and thus the progression of PD [19, 20].
Moreover, DNA methylation and histone acetylation have recently been identified as playing a
role in depression [21], an important feature of neurodegenerative diseases [22]. Emerging evi-
dence shows that epigenetic mechanisms contribute to the process of learning and memory
formation [23, 24]. Despite this evidence, to date, a comprehensive assessment of the role of
epigenetic mechanisms in the development of AD and PD has not yet been done.
Therefore, we aimed to systematically review all available evidence in humans to assess the
association of DNA methylation and histone modifications with the neurodegenerative disor-
ders AD and PD.
Materials and Methods
Literature Search
This review was conducted using a predefined protocol in accordance with the PRISMA [25]
and MOOSE [26] guidelines (S1 File and S2 File). Eleven bibliographic databases (Embase.
com, Medline (Ovid), Web-of-Science, Scopus, PubMed, Cinahl (EBSCOhost), Cochrane
Central, ProQuest, Lilacs, Scielo and Google Scholar) were searched until July 11th 2016 (date
last searched) without any language restrictions, with the help of an experienced medical infor-
mation specialist (WMB). The search strategy combined terms related to exposure (e.g., epige-
netics, DNA methylation, histone, CpG) and outcomes (e.g., neurological disorders, dementia,
Alzheimer, Parkinson). In databases where a thesaurus was available (Embase, Medline and
Cinahl) articles were searched by thesaurus terms, title and/or abstract; other databases were
searched only by title and/or abstract. We restricted the search to studies on human adults.
The full search strategies of all databases are provided in S3 File. After eliminating duplica-
tions, we identified a total of 6927 potentially relevant citations. We retrieved reference lists of
the studies and sought contact with experts to find further relevant publications.
Study Selection and Inclusion Criteria
Included studies either described an association between epigenetic marks (global, site specific
or genome-wide methylation of DNA) or histone modifications (methylation, phosphoryla-
tion, acetylation, ubiquitylation, and sumoylation) and neurodegenerative outcomes defined
as AD and PD. There was no restriction based on the tissue type examined for epigenetic
marks, and therefore, epigenetic marks assessed in any tissue (e.g. brain, blood) were included.
We included cross-sectional, prospective, case-cohort and nested case control studies. Studies
were excluded if they (i) examined epigenetic marks other than DNA methylation and histone
modifications, such as noncoding RNAs; (ii) examined neurodegerative diseases other than
AD and PD, such as Huntington’s disease, Prion disease, Motor neurone diseases, Spinocere-
bellar ataxia, Spinal muscular atrophy; (iii) were case studies or letters to the editor. Two inde-
pendent reviewers (KW/JM and KD/JN/TP/BK/AZ) screened the retrieved titles and abstracts
and selected eligible studies. In cases of disagreement, decision was made through consensus
or consultation with a third independent reviewer (TM). Full texts were retrieved for studies
that satisfied all selection criteria.
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Data Extraction
A predesigned data collection form was prepared to extract the relevant information from the
selected studies, including study design, study population, location, age range, duration of fol-
low up (for longitudinal studies), confounders, tissue sample, method used to assess epigenetic
marks, type and numbers of neurodegenerative outcomes and reported measures of associa-
tions (e.g., correlation analysis, odds ratio, relative risks, confidence intervals). Two indepen-
dent authors (KW and JM/TM) extracted the data.
Assessing the risk of bias
Bias within each individual study was evaluated by two independent reviewers (KW and JM)
using the validated Newcastle-Ottawa Scale, a semi-quantitative scale designed to evaluate the
quality of nonrandomized studies [27]. The scores are provided in S5 File. Study quality was
judged based on the selection criteria of participants, comparability of cases and controls, and
exposure and outcome assessment. Studies that received a score of 9 stars were judged to be at
low risk of bias; studies that scored 7 or 8 stars were considered to be at medium risk; those
that scored 6 or less were considered to be at high risk of bias.
Outcome Assessment
For each study, we defined whether an association was reported and whether direction and
effect sizes were reported, when applicable.
Results
We identified 6927 potentially relevant publications (Fig 1) after removal of duplicate cita-
tions. Based on the title and abstracts, 107 articles were selected for detailed evaluation of their
full texts. Of those, 32 articles were excluded for either having the wrong exposure or outcome
(n = 28), reporting results from animal models (n = 3), or unavailable full texts (n = 1) (Fig 1
and S4 File). Seventy-five articles, based on 73 unique case-control studies, met our eligibility
criteria and were included in this review.
Summary of Included Studies
Overall, 11453 individuals were included within the systematic review, with a total of 2640 for
AD and 2368 for PD outcomes. Of the 73 unique studies included, 13 studies assessed global
DNA-methylation, 45 studies assessed DNA methylation in specific candidate genes, 8 studies
used genome-wide approaches, 1 study assessed both global DNA methylation, histone modi-
fications and DNA methylation in specific candidate genes, and 6 studies examined histone
modifications in relation to ND (Tables 1–3). Twenty-nine studies assessed DNA methylation
and/or histone modifications only in blood, 35 in the brain tissue, 8 studies in both blood and
brain tissue and 1 study assessed methylation in skin fibroblasts. Fifty-seven studies examined
AD as an outcome while 18 studies examined PD. Twenty-four studies included participants
from USA, 11 studies from China, 4 studies included participants from more than 1 country
and the rest included participants solely from Canada, Germany, United Kingdom, Italy,
Spain, Japan, Sweden, Columbia, Australia, New Zealand, Serbia or Brazil (Tables 1–3). Three
studies were judged at low risk of bias whereas the rest were at medium and high risk of bias
(S4 File).
DNA Methylation and Neurodegenerative Diseases
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Global DNA Methylation
Global methylation refers to the overall level of methylcytosine in the genome, expressed as per-
centage of total cytosine. Many of the methylation sites within the genome are found in repeat
sequences and transposable elements, such as Alu and long-interspersed nuclear element
(LINE-1). They correlate with the total genomic methylation content. Measurements of methyl-
ation of the repetitive elements in the genome are used as a surrogate measurement for the over-
all methylation of the genome. Some studies quantified global DNA methylation by calculating
the amount of methylated cytosines in the sample (5 mc) relative to global cytidine (5mC + dC)
in a positive control. Other methods to assess global genomic DNA methylation (e.g., Lumino-
metric Methylation Assay (LUMA) and the [3H]-methyl acceptance based method) are primar-
ily based on the digestion of genomic DNA by restriction enzymes HpaII, MspI and Dpn I.
Thirteen studies examined the association between global DNA methylation and AD
(Table 1). Eight studies assessed DNA methylation in brain tissue and the rest of the studies
assessed it in blood cells. Seven studies assessed global DNA methylation as a percentage of
5-methylcytosine in samples from brain. Of these seven studies, three studies [28–30] found
lower levels of methylation in AD cases compared to controls, two studies [31, 32] found no
Fig 1. Flowchart of studies investigating epigenetic marks in relation to Alzheimer’s disease and
Parkinson’s disease.
doi:10.1371/journal.pone.0167201.g001
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difference, and two other studies [33, 34] reported higher levels of methylation in AD subjects.
One study [35] reported an increase in DNA 5-hydroxymethylation levels in AD compared to
age-matched controls. One study [36] assessed global DNA methylation in LINE-1 elements
in blood and showed no difference between AD patients and healthy controls. One study [16]
examined global DNA methylation in both LINE-1 and Alu elements. It reported no difference
in global DNA methylation levels in Alu elements, and reported higher levels of methylation
in LINE-1 elements in blood cells of AD compared to healthy controls. Three studies used
other methods to assess global DNA methylation: two studies [37, 38] reported DNA hyper-
methylation in AD individuals whereas one study [39] showed no difference in global DNA
methylation between AD cases and controls.
There was only one study that examined the association between global DNA methylation
at LINE-1 elements in blood and PD. The study showed no association [40] (Table 1).
Gene Specific DNA Methylation
DNA methylation, the addition of a methyl group to the 5’ position of cytosine in a dinucleo-
tide CpG site, is an important mechanism in gene expression regulation. The direction of asso-
ciation between DNA methylation and gene expression depends on where within the gene
sequence the methylation occurs. DNA methylation in the promoter region of the gene down-
regulates its expression whereas higher methylation in the gene body may promote the expres-
sion of the gene [41]. However, in most instances DNA methylation represses gene expression.
It is thought that methylation of DNA either directly prevents binding of DNA transcription
factors, or it recruits proteins that bind to methylated DNA. Recruiting proteins may prevent
transcription by influencing chromatin structure by histone modification [41, 42]. The effects
of DNA methylation allow for the evaluation of gene function by comparing individuals who
have the methylated or unmethylated versions of a gene. These methylation patterns can be
studied both in a candidate gene approach or a genome-wide approach.
1. Candidate Gene Studies. Thirty-four studies examined methylation sites in or near
known candidate genes for AD susceptibility in relation to AD (Table 2). The 34 studies
showed that AD cases, compared to controls, have a higher degree of methylation of OPRK1,
UQCRC1,AR, BDNF and HTERT in blood cells, BDNF, synaptophysin gene, CREB promoters,
APOE, TREM 2, TBX2AR, SORBS3 and SPTBN4 in the brain, and lower methylation levels of
2-5a-synthetase gene in skin fibroblasts, PIN1, FAAH, ALOX5 and DR4 gene in blood cells,
TNFA, COX-2, NF-kβ gene and S100A2 and CRTC1 in the brain tissue. The most consistently
reported epigenetic associations with AD were that of methylation at BDNF [34, 43, 44] in
both blood and brain tissue, and at SORBS3 [45, 46] in the frontal cortex, which were reported
in three and two studies respectively. However, one study [46] did not find a difference in DNA
methylation of BDNF gene in AD brain compared to healthy controls. The most studied epige-
netic mark in relation to AD was the methylation pattern of the APP gene. The APP gene was
investigated in five studies: three studies (two studies using brain samples [47, 48] and one study
using blood cells [49]) showed hypomethylation of APP in AD cases compared to controls.
Alternatively, two studies [50, 51] showed no difference in DNA methylation of APP in brain tis-
sue between AD and healthy controls. Fourteen studies found no difference or clear pattern in
methylation of the following genes: 12-LOX [34], debrin-like protein gene [34], p450 epoxygen-
ase gene [34], MAPT, PSEN1,UCHL1, SST [52], SSTR4 [52], F2RL2 [45], SOD-1 [48] and GRN
[53] in brain tissue; PS1 [49], PS2 [49] and tau1 [49], SMARCA 5 [54], CHD1 [54], BDNF [55],
SIRT1 [55], PSEN1 [55{Tannorella, 2015 #2823], genes involved in DNA repair [56], genes
involved in homocysteine pathway [57], CTSB [58], CTSD [58], DDT [58], TSC1 [58], NRD1
[58] and NDUFA6 [58] in blood cells; HSPA8 [59], HSPA9 [59], ApoE4 [47, 49], SNAP25 [60],
DNA Methylation and Neurodegenerative Diseases
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SORL 1, SIRT1 and SIRT3 [49, 54, 60] in both blood cells and brain tissue (Table 2). However, 7
studies showed differences in methylation patterns of CpG sites (within same gene some CpG
sites were hypomethylated and some others were hypermethylated, in AD cases) examined at
the following genes: SORL1 [61], ABCA7 [61], SLC2A4 [61], BIN1 [61], HSPA8 [59], HSPA9
[59], DR4 gene [62], BDNF4 [43, 44], SIRT1 [49], APP [47], MAPT [47] and GSK3B [47].
There were 13 studies that examined methylation sites in or near known candidate genes
for PD susceptibility (Table 3). Overall the studies looking at PD found lower levels of methyl-
ation of NAPS2 and NOS2 in blood cells and of ADORA2A in the brain tissue of PD cases, and
higher levels of methylation of PGC−1α gene in brain tissue of PD patients. Six studies exam-
ined the methylation pattern of α-synuclein gene (SNCA) in blood and brain tissue in relation
to PD: 5 studies [19, 62–65] showed significantly decreased levels of methylation in PD
patients compared to controls whereas 1 study [66] found a non-significant decrease in PD
subjects. Four studies [53, 67–69] did not show any difference in DNA methylation of the fol-
lowing genes: Parkin gene, DJ-1, PER1, PER2, CRY1, CRY2, CLOCK and BMAL1 in blood cells
and of GRN in brain tissue. One study [70] examined DNA methylation of the MAPT gene in
blood cells and different areas of the brain and showed that the association between DNA
methylation of MAPT and presence of PD differ by the tissue examined.
2. Genome-wide analysis. Six studies looked for differentially methylated sites associated
with AD in brain tissue; 1 study also looked in both brain tissue and blood cells (Table 2). Up
to 1106 CpG sites were reported to be differentially methylated in the brains of AD cases com-
pared to individuals without AD. One study [71] found 948 CpGs representing 918 unique
genes in the frontal cortex were associated with late onset-AD status. In AD cases, there was
mainly hypermethylation of genes related to molecular and biological processes involved in
transcription, and hypomethylation of genes related to membrane transport and protein
metabolism (e.g. TMEM59). One study reported that out of 137 CpGs in cortical brain tissue
found to relate with the burden of natriuretic amyloid plaques (NP), 22 were also associated
with the presence of AD [72]. Another study [73] reported 1106 CpGs to be differentially
methylated in late onset-AD subjects compared to healthy controls and that 87,3% of the CpG
sites were hypomethylated. Among the CpGs found to differ in methylation frequency
between AD patients and healthy controls in the initial analysis, only the hypermethylation of
DUSP22 gene in AD cases could be confirmed in the replication set [74]. Two other studies
[75, 76] reported that differentially methylated regions in the brain tissue of AD patients were
related to genes involved in neurogenesis, neuronal projection development and regulation of
neuron differentiation, as well as β-amyloid and tau metabolism.
Two studies conducted an epigenome-wide association study approach for PD. One study
reported hypomethylation of CYP2E1, PPP4R2 and MGC3207 and hypermethylation of
DEFA1 and CHFR in the putamen and cortex of PD cases compared to controls [77]. Another
study [78] found 2908 CpGs (317 hypermethylated and 2591 hypomethylated) in the brain tis-
sue and 2897 CpGs (476 hypermethylated and 3421 hypomethylated) in the blood cells of PD
patients to be differentially methylated compared to controls. The study found that 30% of the
differentially methylated sites presented concordant changes in methylation between blood
and brain. The identified genes were enriched for genes (known from genome-wide associa-
tion studies) with epigenetic changes in biological pathways relevant to PD-development, such
as cell communication and apoptosis (Table 3).
Histone Modifications and Neurodegenerative disorders
Five studies [34, 79–82] examined histone modification in relation to AD. There were no con-
sistent findings on the role of H3 or H4 acetylation in AD (Table 1). However, one of the
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studies [34] showed increased H3 phosphorylation in AD brains compared to age-matched
controls (Table 1).
There were two studies [83, 84] examining the role of histone modifications in PD. They
mainly showed an increase in levels of histone acetylation in PD patients.
Discussion
We have systematically reviewed the current knowledge about epigenetic associations with
Alzheimer’s disease (AD) and Parkinson’s disease (PD). There is some evidence that DNA
methylation may be related to the risk of neurological disease. Among gene-specific studies,
DNA methylation at 24 genes was found to be associated with AD, while 7 genes were differen-
tially methylated in PD.
The present review finds inconsistent associations between global DNA methylation and
AD. These results are in line with previous studies showing contradictory results when study-
ing the relationship between global DNA methylation and other health outcomes, including
cardiovascular disease and diabetes [85–91]. The use of different methods for assessing global
DNA methylation, including the 5-methylcytosine ratio and the methylation of LINE-1 and
Alu repeat elements, may account for some of these differences. LINE-1 and Alu repeat ele-
ments are used as a measure of global DNA methylation due to their ubiquitous presence in
the genome. However, as they may have different functions, the resulting differences in meth-
ylation may explain some of the conflicting results [92]. DNA methylation at Alu is about one-
third to one-fourth of methylation at LINE-1. The difference may suggest that epigenetic
changes at LINE-1 and Alu measure different traits [92]. Global DNA methylation assessed by
LUMA modestly correlates with LINE-1 methylation, suggesting that the differences in the
reported results may come from the assay used to assess global DNA methylation [93]. Fur-
thermore, as different tissue types (brain tissue or peripheral blood samples) are assessed
between studies, tissue-specific DNA methylation patterns may partially explain the heteroge-
neous findings. Even within studies performed on brain tissue, samples are obtained from dif-
ferent areas of the brain, including cortical, cerebellar, and hippocampal tissue. This difference
may limit comparability of the results as specific brain regions comprise different cell popula-
tions (astrocytes, neurons, microglia, oligodendrocytes). Furthermore, the same methylation
pattern, depending on its position toward coding gene, can have different effects [41, 94].
Therefore, global DNA methylation provides an oversimplified assessment of epigenetic dysre-
gulation, as it neither quantitatively nor qualitatively acknowledges the co-existence of hypo-
and hypermethylation within a gene or distinct genes within the same cell.
In our review, several genes were found to be differentially methylated in brain tissue or
peripheral blood of AD patients when compared to controls. In particular, brain derived neu-
rotrophic factor (BDNF) and SORBS3were each found in two different studies to be signifi-
cantly more methylated in AD patients than in controls. These results parallel previous studies
showing an association between BDNF hypermethylation in blood and depression, depressive
symptoms and antidepressants response [95]. Similarly, previous studies have reported hyper-
methylation of BDNF and of its receptor (Tropomyosin-Related Kinase B) in brains of individ-
uals who have committed suicide [96, 97]. BDNF is a secretory protein with neuroprotective
effects [98] which has been shown to be associated with neurodegenerative diseases, including
AD, PD and Huntington’s disease [99]. BDNF was shown to be hypermethylated in the periph-
eral blood of AD patients compared to controls, indicative of decreased expression of BDNF.
This is consistent with findings in brain tissue of patients diagnosed postmortem with AD [34]
and with other studies showing that BDNF promoter methylation is related to BDNF mRNA
expression [97]. As BDNF is able to cross the blood-brain barrier [100], DNA methylation in
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the peripheral tissue may exert effects on neuronal tissue and vice versa, highlighting the
potential utility of peripheral BDNF methylation as a biomarker for AD. This is supported by
the overlap of epigenetic changes in both AD-brain tissue and peripheral blood reported in
this review. SORBS3 is involved in neuronal signaling [101] and regulation of gene expression
[102], and was found in two studies to be hypermethylated in the frontal cortex of AD patients.
However, its role in the pathogenesis of AD and whether methylation of SORBS3 is consistent
across tissue types remains to be investigated.
Also, genes of proteins implicated in AD pathogenesis, such as CREB, were differentially
methylated in PD, but the evidence is too limited to draw a firm conclusion. AD is associated
with a reduction of CREB activation. CREB is a histone acetyltransferase that functions as a co-
activator that catalyzes histone acetylation, causing a decrease in the transcription of memory-
associated genes, and therefore, leading to memory impairment [103]. Treatment targeting the
transcription machinery interacting with CREB during memory formation has been suggested
to be a useful strategy for treating AD [103]. Furthermore, genes of proteins such as death recep-
tor 4 (DR4) and NF-kB are involved in processes that may play a role in the pathogenesis of AD
such as apopotosis and/or inflammation. DR4 and NF-kB genes were reported to be differen-
tially methylated in AD cases [104, 105]. DR4 might impair the apoptotic signal transduction
and may cause apoptosis of brain cells[104]. Polymorphisms of the DR4 gene have been shown
to influence susceptibility to AD [104]. NF-kB activation is a common feature of many neurode-
generative diseases, particularly of AD [105]. Activation of NF-kB leads to the expression of a
large variety of pro-inflammatory molecules such as cytokines and chemokines, which could be
in part responsible for the neurotoxicity seen in AD [105]. The interaction of methylation of
these genes with molecular pathways and how this affects risk of AD remains to be elucidated.
In PD patients, SNCA was consistently found to be hypomethylated in both peripheral
blood cells and brain tissue. Known to be a causative gene of familial PD [106], the overexpres-
sion of SNCA in sporadic PD cases [107–109] suggests a role in the pathogenesis of sporadic
PD as well. The finding that SNCA is similarly hypomethylated in both peripheral blood and
in brain tissues is in line with previous studies and indicates it may be useful as a biomarker in
sporadic PD.
Also, several other genes involved in the pathogenesis of PD were reported to be differen-
tially methylated in PD cases, including NOS2 (hypomethylated), ADORA2A (hypomethylated),
and CYP2E1 (hypomethylated). NOS2, the gene coding for inducible nitric oxide synthase
(iNOS) is primarily regulated at the transcriptional level, at least partially via DNA methylation
[110]. Hypomethylation of CpG sites in the 50 promoter region of the gene might increase iNOS
expression [110]. Increased iNOS expression in turn promotes inflammation and may lead to
PD [111]. In line with this evidence, a selective iNOS inhibitor, GW274150 ([2-[(1-iminoethyl)
amino] ethyl]-L-homocysteine) has been reported to have a neuroprotective effect in a model of
PD [112]. ADORA2A is the gene coding for adenosine A2A receptor (A2AR), which is highly
expressed in the striatum. ADORA2Apolymorphisms have been inversely associated with PD
risk [113]. Also, A2AR antagonists are effective in relieving parkinsonian motor symptoms and
have been suggested as potential new drugs for PD treatment [114]. CYP2E1 codes for Cyto-
chrome P450 2E1, a member of the Cytochrome P450 enzyme family, which represent a major
part of the cellular defense against xenobiotic exposure and have been implicated in PD patho-
physiology since the mid-1980s [115]. Decreased methylation of CYP2E1 is related to increased
expression of CYP2E1 messenger RNA in PD patients [77]. Enhanced CYP2E1 activity has
been suggested to contribute to dopaminergic neurodegeneration in PD [115, 116].
This review demonstrated that while epigenetic changes in AD and PD patients have been
investigated via global methylation and gene-specific methylation studies, findings are lacking
regarding histone modification. Histone modifications are another epigenetic mark that play a
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pivotal role in the epigenetic regulation of transcription and other functions in cells, including
neurons [117]. Posttranslational histone modifications interfere with the transcriptional pro-
gram inducing long-lasting phenotypic changes in neural plasticity including learning and mem-
ory [118, 119]. Many enzymes are involved in the regulation of histones including processes
such as acetylation, methylation, phosphorylation, sumoylation and ubiquitination, which may
play important roles in the pathogenesis of ND [120]. Histone deacetylases (HDACs) has been
reported to be active in these processes. Valproic acid, an inhibitor of HDACs, demonstrates
neuroprotection against rotenone in a rat model of PD [121]. Also in AD and PD animal models,
histone acetylation has been linked to neurodegeneration [120, 122]. One study in Huntington’s
disease patients found that most of the identified histone modifications in the brain are associ-
ated with genes that have known roles in neuronal signaling [123]. Those findings suggest that
histone modifications may be a relevant form of epigenetic change in patients of neurological
diseases. Therefore, much information may still be gained from histone modification studies in
AD or PD patients.
The strengths and limitations of the findings from this review merit careful consideration.
The present report involves data from nearly 11,453 individuals. It is the first systematic review
on the subject that has critically appraised the literature following an a priori designed protocol
with clearly defined inclusion and exclusion criteria. Using a systemic search in medical data-
bases, few reviews evaluating the role of epigenetics marks in AD and PD were found [124–
126]. Existing reviews were all narrative reviews (not performed systematically). Narrative
reviews do not involve a systemic search and they are often focused on a subset of studies in
the chosen area based on availability of the author selection. Therefore, they are more likely to
experience selection bias. A number of limitations, however, need to be considered. The
majority of studies included in our systematic review are cross-sectional assessments, making
it difficult to draw conclusions on causality. Also, studies investigating epigenetic dysregula-
tion in neurological diseases suffer from small sample size, the consequences of which include
reduced statistical power and increased false discovery rates. In addition, although most of the
epigenetic studies included in this review adjusted for age and sex and sampled from an ethni-
cally homogenous population, a number of analyses are lacking adjustment for lifestyle and
environmental factors. Factors including smoking and alcohol consumption are important
risk factors for neurological disorders and can alter epigenetic mechanisms. Furthermore,
when assessing epigenetic modifications, studies used different techniques, which may pro-
duce heterogeneous results. Also, genetically, AD and PD are usually divided into familial
cases with Mendelian inheritance and sporadic cases with no familial aggregation [127]. The
sporadic form is more complex and likely results from a combination of genetic and environ-
mental influences. Therefore, examining whether epigenetic marks may have different role in
the etiology of AD and PD types would be interesting [127]. Most of the studies included in
this review used post-mortem brain tissue, which can help to provide several insights about
the nature of epigenetic medications in relation to neurodegenerative diseases, but can also
present several limitations. Using post-mortem brain is problematic with respect to temporal-
ity between exposure and outcome[128]. Second, untangling real effects from confounders
(such as medications) can be challenging. Lastly, death often involves acidosis, which can
alter genetic material, increasing the likelihood of misclassifying epigenetic modification and
increasing the chances of spurious findings [129, 130].
Conclusion
Overall, the findings from this review indicate that there are significant epigenetic differences
between patients with neurodegenerative diseases and healthy individuals. Furthermore,
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candidate gene studies have shown that some genes known to play a role in maintenance and
function of neurological tissues are differentially methylated in diseased individuals. In addi-
tion, a number of these genes, such as BDNF in AD patients and SNCA in PD patients, are sim-
ilarly methylated in blood and brain tissue. Along the same lines, Epigenetic Wide Association
Studies show that differentially methylated sites in neurological disorders present concordant
changes in methylation between blood and brain. These data suggest that studies in peripheral
blood can provide valuable information on the neuronal epigenetic changes and their conse-
quences on cell function. Therefore, methylation profiling in peripheral blood to identify neu-
rological disorders-related methylated regions has a high potential clinical utility. It may allow
clinicians to identify high-risk individuals who may benefit from preventive and therapeutic
interventions. However, due to the mostly cross-sectional design of included studies and lack
of replication in the case of new findings, there remain many questions about the temporal
relation between epigenetic modifications and neurological diseases, as well as the significance
of the findings in disease pathology. Also, given the reversible nature of epigenetic aberrations,
targeting the epigenome can be a novel preventive strategy and treatment for AD and PD.
There is evidence showing that methyl donors such as folate and vitamin B12 may affect DNA
methylation and the risk for several neurodegenerative conditions, including AD and PD [131,
132]. Studies from animal studies show that histone deacetylase inhibitors lowers Aβ levels
and improves learning and memory in a mouse model of Alzheimer’s disease. Those findings
provide support that histone deacetylase inhibitors may serve as a novel therapeutic strategy
for AD [133]. Epigenetic therapy has been shown to successfully reverse several epigenetics
marks and disease symptoms and have been approved by the FDA for use in cancer [134].
Therefore, studies in larger cohorts with longitudinal design may help to close the gap on iden-
tifying epigenetic changes that have clinical significance and could lead to strategies for inter-
vention in neurological diseases.
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